The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Authors :: Shivam Rai
Jan Stetka
MARC Usart
Hui Hao-Shen
Young Park
Remie Houston
Anthony R. Martinez Benitez
Matthew Wereski
Emily Guzzardi
Sonali Persaud
Hailey Ramzan
Alan Futran
Charley Xu
Jeremy Greenwood
Sayan Mondal
Craig Masse
Ross L. Levine
Radek C. Skoda
Andrew Dunbar
Source :: Blood. 140:6722-6723
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools